CB 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

CB 2 cannabinoid receptor-selective agonists are promising candidates for the treatment of pain. CB 2 receptor activation inhibits acute, inflammatory, and neuropathic pain responses but does not cause central nervous system (CNS) effects, consistent with the lack of CB 2 receptors in the normal CNS... View More